Here’s a startling fact: age often complicates treatment decisions in advanced prostate cancer, leaving many patients and doctors unsure about the best path forward. But what if a treatment could defy age-related limitations and offer consistent benefits across all age groups? That’s exactly what the latest data on rucaparib (Rubraca) suggests for patients with BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC). And this is the part most people miss: the benefits of rucaparib not only hold steady but actually strengthen in older patients, challenging conventional wisdom about cancer treatment in the elderly. Let’s dive into the details and explore why this matters.
Updated findings from the phase 3 TRITON3 trial (NCT02975934) reveal that rucaparib significantly improves radiographic progression-free survival (rPFS) compared to physician’s choice of therapy—whether it’s docetaxel or androgen receptor pathway inhibition (ARPI)—regardless of the patient’s age. But here’s where it gets controversial: while many treatments show diminishing returns in older patients, rucaparib’s effectiveness appears to increase with age, particularly in those 75 and older, who saw a remarkable 59% reduction in the risk of radiologic progression. This raises a thought-provoking question: Could rucaparib be a game-changer for elderly patients who are often underrepresented in clinical trials?
Presented at the 26th Annual Meeting of the Society of Urologic Oncology, the data showed that across the entire BRCA-mutated population, rucaparib provided a median rPFS of 11.2 months compared to 6.4 months with physician’s choice (HR, 0.50; 95% CI, 0.36-0.69). When broken down by age, the results were equally compelling. Patients under 65, between 65 and 74, and 75 or older all experienced a median rPFS of 11.2 months with rucaparib, compared to 6.3, 7.6, and 5.4 months, respectively, with physician’s choice. This consistency across age groups is rare in oncology and underscores rucaparib’s potential as a versatile treatment option.
Top Takeaways from TRITON3:
1. Age is just a number: Rucaparib’s rPFS benefits were consistent across all age groups, making it a reliable choice for BRCA-mutated mCRPC patients of any age.
2. Older patients, bigger gains: Patients aged 75 and older saw the greatest relative risk reduction (59%) in radiologic progression, challenging the notion that older patients respond less favorably to treatment.
3. Safety first: Rucaparib’s safety profile remained manageable, with expected side effects like fatigue and anemia. While anemia rates were higher in older patients, no major age-related safety concerns emerged.
Alan H. Bryce, MD, and colleagues emphasized in their poster presentation, “These findings support the use of rucaparib as a treatment option in patients with BRCA-mutated mCRPC independent of age.” But this raises another question: If rucaparib is so effective across age groups, why isn’t it more widely adopted in clinical practice? Could cost, accessibility, or lack of awareness be barriers?
The TRITON3 study was an open-label, randomized phase 3 trial that enrolled chemotherapy-naive mCRPC patients with BRCA1/2 or ATM alterations who had previously received a second-generation ARPI. Participants were randomized 2:1 to receive 600 mg of rucaparib twice daily or physician’s choice of therapy. The primary endpoint was rPFS, with key secondary endpoints including overall survival (OS) and objective response rate (ORR). Primary data from the study confirmed that rucaparib significantly prolonged imaging-based PFS compared to physician’s choice, with a median PFS of 10.2 months versus 6.4 months (HR, 0.61; 95% CI, 0.47-0.80; P < .001).
In May 2020, the FDA granted accelerated approval to rucaparib for BRCA-mutated mCRPC patients who had previously received androgen receptor–directed therapy and taxane-based chemotherapy, based on findings from the phase 2 TRITON2 trial. However, the updated TRITON3 data further solidify rucaparib’s role as a cornerstone treatment, particularly for older patients who often face limited options.
Demographics and Safety: Across age groups, the majority of patients were White, with varying rates of metastases and prior therapies. The safety profile of rucaparib was consistent, with fatigue, anemia, nausea, decreased appetite, and diarrhea being the most common side effects. While anemia rates increased with age, the overall safety profile remained manageable, making rucaparib a viable option even for frailer patients.
Final Thoughts: Rucaparib’s ability to deliver consistent benefits across all age groups—and even enhance those benefits in older patients—is a significant breakthrough in mCRPC treatment. But it also sparks debate: Are we underutilizing this drug? And how can we ensure equitable access for all patients, regardless of age or socioeconomic status? Let’s continue the conversation in the comments—do you think rucaparib should be the standard of care for BRCA-mutated mCRPC, or are there still hurdles to overcome?
